Stock listing
Frankfurt:OL0 Devyser Diagnostics AB Aktie
German listing (Frankfurt) of Devyser Diagnostics AB · home listing Stockholm:DVYSR
Follow Devyser Diagnostics AB into a list and get an email when it puts out news.
Share price · FWB:OL0
€5.24 EUR -0.36 (-6.4%)
Close on Nov 20, 2026
- Day range
- €5.24 – €5.55 EURNov 20, 2026
- 52-week range
- €4.38 – €10.79 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:DVYSR · Home | 60.00 SEK | -2.80 (-4.5%) | 24,844 | 62.30 | 62.50 | 59.00 | 62.80 | Close on Nov 20, 2026 |
| Frankfurt:OL0 | €5.24 EUR | -0.36 (-6.4%) | — | €5.55 | €5.55 | €5.24 | €5.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:OL0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €5.862 | -0.25 | -4.1% | €6.053 | €6.102 | €5.775 | 0 | |
| €6.112 | +0.293 | +5.0% | €5.776 | €6.172 | €5.772 | 0 | |
| €5.819 | +0.021 | +0.4% | €5.836 | €5.912 | €5.761 | 0 | |
| €5.798 | +0.281 | +5.1% | €5.716 | €5.798 | €5.674 | 0 | |
| €5.517 | +0.514 | +10.3% | €5.027 | €5.538 | €4.97 | 0 | |
| €5.003 | -0.24 | -4.6% | €5.214 | €5.279 | €4.966 | 0 | |
| €5.243 | -0.104 | -1.9% | €5.288 | €5.289 | €5.205 | 0 | |
| €5.347 | +0.613 | +12.9% | €4.927 | €5.365 | €4.919 | 0 | |
| €4.734 | +0.18 | +4.0% | €4.496 | €4.735 | €4.495 | 0 | |
| €4.554 | -0.035 | -0.8% | €4.548 | €4.612 | €4.531 | 0 | |
| €4.589 | +0.096 | +2.1% | €4.503 | €4.601 | €4.458 | 0 | |
| €4.493 | +0.015 | +0.3% | €4.496 | €4.496 | €4.474 | 0 | |
| €4.478 | -0.008 | -0.2% | €4.508 | €4.553 | €4.432 | 0 | |
| €4.486 | +0.008 | +0.2% | €4.498 | €4.541 | €4.438 | 0 | |
| €4.478 | -0.034 | -0.8% | €4.495 | €4.506 | €4.428 | 0 | |
| €4.512 | +0.115 | +2.6% | €4.489 | €4.57 | €4.455 | 0 | |
| €4.397 | -0.112 | -2.5% | €4.414 | €4.424 | €4.396 | 0 | |
| €4.509 | +0.039 | +0.9% | €4.526 | €4.526 | €4.507 | 0 | |
| €4.47 | -0.007 | -0.2% | €4.442 | €4.471 | €4.423 | 0 | |
| €4.477 | -0.047 | -1.0% | €4.483 | €4.483 | €4.444 | 0 | |
| €4.524 | -0.075 | -1.6% | €4.535 | €4.559 | €4.455 | 0 | |
| €4.599 | -0.08 | -1.7% | €4.634 | €4.658 | €4.504 | 0 | |
| €4.679 | -0.089 | -1.9% | €4.743 | €4.78 | €4.658 | 0 | |
| €4.768 | +0.057 | +1.2% | €4.696 | €4.784 | €4.693 | 0 | |
| €4.711 | +0.004 | +0.1% | €4.767 | €4.792 | €4.705 | 0 | |
| €4.707 | +0.26 | +5.8% | €4.535 | €4.71 | €4.458 | 0 | |
| €4.447 | +0.047 | +1.1% | €4.45 | €4.45 | €4.447 | 0 | |
| €4.40 | -0.089 | -2.0% | €4.403 | €4.405 | €4.378 | 0 | |
| €4.489 | -0.005 | -0.1% | €4.49 | €4.497 | €4.455 | 0 | |
| €4.494 | -0.033 | -0.7% | €4.524 | €4.544 | €4.485 | 0 | |
| €4.527 | -0.094 | -2.0% | €4.528 | €4.528 | €4.527 | 0 | |
| €4.621 | -0.04 | -0.9% | €4.648 | €4.66 | €4.616 | 0 | |
| €4.661 | +0.014 | +0.3% | €4.648 | €4.671 | €4.608 | 0 | |
| €4.647 | -0.031 | -0.7% | €4.652 | €4.658 | €4.627 | 0 | |
| €4.678 | -0.042 | -0.9% | €4.696 | €4.699 | €4.669 | 0 | |
| €4.72 | -0.106 | -2.2% | €4.833 | €4.854 | €4.651 | 0 | |
| €4.826 | +0.065 | +1.4% | €4.831 | €4.837 | €4.804 | 0 | |
| €4.761 | -0.054 | -1.1% | €4.754 | €4.771 | €4.736 | 0 | |
| €4.815 | -0.10 | -2.0% | €4.817 | €4.829 | €4.806 | 0 | |
| €4.915 | -0.038 | -0.8% | €4.917 | €4.917 | €4.90 | 0 | |
| €4.953 | -0.098 | -1.9% | €4.968 | €5.052 | €4.903 | 0 | |
| €5.051 | -0.184 | -3.5% | €5.222 | €5.234 | €5.015 | 0 | |
| €5.235 | -0.045 | -0.9% | €5.285 | €5.306 | €5.201 | 0 | |
| €5.28 | -0.016 | -0.3% | €5.375 | €5.382 | €5.272 | 0 | |
| €5.296 | -0.093 | -1.7% | €5.315 | €5.338 | €5.285 | 0 | |
| €5.389 | +0.091 | +1.7% | €5.399 | €5.40 | €5.33 | 0 | |
| €5.298 | +0.075 | +1.4% | €5.25 | €5.321 | €5.247 | 0 | |
| €5.223 | +0.035 | +0.7% | €5.228 | €5.229 | €5.223 | 0 | |
| €5.188 | -0.049 | -0.9% | €5.228 | €5.255 | €5.178 | 0 | |
| €5.237 | -0.133 | -2.5% | €5.241 | €5.244 | €5.229 | 0 | |
| €5.37 | +0.037 | +0.7% | €5.39 | €5.395 | €5.294 | 0 | |
| €5.333 | -0.018 | -0.3% | €5.34 | €5.349 | €5.333 | 0 | |
| €5.351 | -0.03 | -0.6% | €5.356 | €5.404 | €5.351 | 0 | |
| €5.381 | +0.081 | +1.5% | €5.362 | €5.413 | €5.287 | 0 | |
| €5.30 | -0.067 | -1.2% | €5.314 | €5.53 | €5.297 | 0 | |
| €5.367 | -0.126 | -2.3% | €5.433 | €5.465 | €5.354 | 0 | |
| €5.493 | +0.063 | +1.2% | €5.53 | €5.548 | €5.487 | 0 |
- Ticker
- Frankfurt:OL0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Apr 27, 2026
Devyser Diagnostics AB publishes quarterly report for the period January to March 2026
Latest earnings call · Jul 20, 2026
Devyser Diagnostics (Stockholm:DVYSR) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 3, 2026
Q3 2026 Earnings Presentation
Earnings · 22 slides
Latest news
Devyser Diagnostics AB publishes quarterly report for the period January to March 2026
Apr 27, 2026
Closed €8.70 (+10.1%) on Apr 27, 2026
Devyser announces that Chief Commercial Officer will leave the company
Apr 7, 2026
Closed €6.94 (+2.5%) on Apr 8, 2026
Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares
Apr 1, 2026
Closed €7.04 (+1.8%) on Apr 1, 2026
Devyser Diagnostics AB publishes year-end report for January to December 2025
Feb 12, 2026
Closed €9.41 (-1.5%) on Feb 12, 2026
Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market
Feb 11, 2026
Closed €9.41 (-1.5%) on Feb 12, 2026
Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test
Nov 28, 2025
Closed €9.95 (+1.7%) on Nov 28, 2025
Devyser Diagnostics AB on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 6 in the last 12 months · 10 in all · newest Apr 27, 2026 · oldest 2025
- Calls
- 10 calls with a replay · 10 with a transcript · latest Jul 20, 2026
- Decks
- 13 decks · latest Nov 3, 2026
Where Devyser Diagnostics AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:DVYSR · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A3C811 | LS Exchange | Germany | EUR |
| gettex:OL0 | gettex | Germany | EUR |
| Lang & Schwarz:A3C811 | Lang & Schwarz | Germany | EUR |
| Munich:OL0 | Munich | Germany | EUR |
| Frankfurt:OL0 · This page | Frankfurt | Germany | EUR |
| Stuttgart:OL0 | Stuttgart | Germany | EUR |
| Dusseldorf:OL0 | Dusseldorf | Germany | EUR |
| OTC:DVYSF | OTC | United States | USD |
Valuation
P/E 39.9× against a median of 25.0×: 4th lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 968.7M SEK
- P/E
- 39.9×
- EV/sales
- 3.8×
- EV/EBITDA
- 17.5×
- Price/book
- 2.6×
- Gross margin
- 80.1%
- Operating margin
- 11.0%
- Net margin
- 10.0%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Devyser Diagnostics AB · OMXSTO:DVYSR | US$99.24M | US$94.86M | 39.9× | 3.8× | 17.5× | 2.6× | 10.0% | 0.1× | n/a |
| Burning Rock Biotech Ltd. · NASDAQ:BNR | US$116.7M | US$60.54M | n/a | 0.8× | n/a | 1.6× | −13.6% | 0.1× | 1.51 |
| BIODYNE Co., Ltd. · KRX:314930 | US$115.0M | US$104.0M | 182× | 19.9× | 70.7× | 3.5× | 12.1% | 0.0× | n/a |
| Photocure ASA · OSL:PHO | US$113.9M | US$97.23M | 22.9× | 1.4× | 6.1× | 1.9× | 7.1% | 0.0× | n/a |
| ArcticZymes Technologies ASA · OSL:AZT | US$108.4M | US$80.84M | 66.1× | 6.2× | 24.6× | 3.0× | 12.7% | 0.0× | n/a |
| NanoenTek, Inc. · KRX:039860 | US$107.8M | US$71.26M | 24.8× | 2.2× | 17.4× | 1.5× | 13.3% | 0.0× | n/a |
| BICO Group AB Class B · OMXSTO:BICO | US$102.7M | US$90.50M | n/a | 0.6× | 2.1× | 0.8× | −28.3% | 0.3× | n/a |
| Quanterix Corporation · NASDAQ:QTRX | US$93.06M | US$47.06M | n/a | 0.3× | n/a | 0.4× | −75.0% | 0.1× | 1.87 |
| Exagen Inc. · NASDAQ:XGN | US$92.10M | US$86.82M | n/a | 1.2× | n/a | 6.7× | −25.1% | 1.7× | 2.52 |
| Biodesix, Inc. · NASDAQ:BDSX | US$83.83M | US$105.4M | n/a | 1.0× | n/a | 9.7× | −25.7% | 5.8× | 1.56 |
| Bonraybio Co. Ltd. · TWSE:6955 | US$81.85M | US$65.60M | 25.0× | 6.5× | 18.1× | 4.1× | 32.5% | 0.0× | n/a |
| Median of the others | US$105.3M | US$83.83M | 25.0× | 1.3× | 17.8× | 2.5× | −3.3% | 0.1× | 1.72 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 100.17 SEK · Analysts' mean
- EPS, year to Dec 2026
- 0.73 · 2 analysts
- Revenue, year to Dec 2026
- 247.1M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jan Wahlström | CEO |
| Niklas Axelsson | CFO |
| Sabina Berlin | VP IR & Corporate Affairs |
| Olle Myrberg | VP Quality & Regulatory Affairs |
| Robin Sortebech | VP Supply Chain |
| Michael Uhlin | CSO |
Board
| Director | Role |
|---|---|
| Mia Arnhult | Chairman |
| Fredrik Dahl | Board member |
| Olof Ericsson | Board member |
| Pia Gideon | Board member |
| Thomas Eklund | Board member |
Events
- Next results
- Feb 16, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Devyser Diagnostics (Stockholm:DVYSR) Q2 2026 Earnings Call | Mon, Jul 20, 2026 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q1 2026 Earnings Call | Mon, Apr 27, 2026 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q2 2025 Earnings Call | Tue, Jul 22, 2025 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 5:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 7:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q2 2024 Earnings Call | Tue, Jul 23, 2024 · 3:00 AM ET | Replay |
| Devyser Diagnostics (Stockholm:DVYSR) Q1 2024 Earnings Call | Wed, May 08, 2024 · 3:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +5.4% |
| Q2 2026 | Jul 19, 2026 · After close | 0.0% |
| Q1 2026 | Apr 27, 2026 · Before open | +7.2% |
| Q4 2025 | Feb 11, 2026 · After close | +3.5% |
| Q3 2025 | Nov 4, 2025 · After close | −9.8% |
| Q2 2025 | Jul 22, 2025 · Before open | +9.8% |
| Q1 2025 | Apr 29, 2025 · Before open | −0.5% |
| Q4 2024 | Feb 13, 2025 · Before open | −7.2% |
| Q3 2024 | Oct 30, 2024 · Before open | −1.5% |
| Q2 2024 | Jul 23, 2024 · Before open | −0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | +5.8% |
| Q4 2023 | Feb 19, 2024 · After close | +7.2% |
| Q3 2023 | Nov 9, 2023 · Before open | +3.1% |
| Q2 2023 | Aug 23, 2023 · Before open | −1.0% |
| Q1 2023 | May 9, 2023 · Before open | −2.8% |
| Q4 2022 | Feb 21, 2023 · Before open | +1.5% |
| Q3 2022 | Nov 10, 2022 · Before open | −1.5% |
| Q2 2022 | Aug 24, 2022 · Before open | −0.2% |
| Q1 2022 | May 11, 2022 · Before open | −0.7% |
| Q4 2021 | Feb 24, 2022 · Before open | −2.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 22 slides | Nov 3, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Jul 20, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 23 slides | Apr 27, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 24 slides | Nov 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 23 slides | Jul 22, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 24 slides | Apr 29, 2025 |
| Investor Day (November 2024) | Investor day | 76 slides | Nov 25, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 21 slides | Oct 30, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 21 slides | Jul 23, 2024 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2024 Earnings Presentation | Earnings | 26 slides | May 8, 2024 |
| Devyser — Q2 2023 Earnings Presentation | Earnings | 21 slides | Aug 23, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 18 slides | May 9, 2023 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 250.5M | 216.9M | 169.3M | 126.6M | 93.5M | 65.7M | 64.3M | 48.1M |
| Cost of revenue | 48.6M | 44.2M | 21.2M | 20.8M | 18.8M | 9.04M | 12.0M | 13.3M |
| Gross profit | 201.9M | 172.7M | 148.1M | 105.8M | 74.7M | 56.6M | 52.3M | 34.8M |
| Research and development | 18.0M | 43.1M | 41.1M | 28.6M | 20.8M | 21.7M | 9.90M | 8.62M |
| Selling, general and administrative | 56.0M | 51.3M | 42.0M | 37.9M | 28.8M | 11.7M | ||
| Operating income | 10.6M | -58.3M | -56.5M | -54.9M | -21.8M | -6.96M | 8.65M | -3.51M |
| Depreciation and amortization | 27.1M | 27.7M | 9.80M | 6.16M | 3.28M | 2.96M | 2.32M | 1.25M |
| EBITDA | 37.7M | -30.6M | -46.7M | -48.8M | -18.5M | -3.99M | 11.0M | -2.27M |
| Interest expense | 13.6M | 3.50M | 800.0K | 500.0K | 939.0K | 925.0K | 785.0K | 596.0K |
| Income before tax | -2.60M | -57.6M | -54.4M | -52.7M | -22.3M | -10.9M | 10.2M | -232.0K |
| Income tax | 5.80M | 3.90M | -800.0K | -6.80M | -1.18M | -985.0K | 2.62M | -751.0K |
| Net income | -8.40M | -61.5M | -53.6M | -46.0M | -20.7M | -10.9M | 7.01M | 519.0K |
| Earnings per share, basic | -0.51 | -3.75 | -3.31 | -2.89 | -1.85 | -3.76 | 2.31 | 0.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 77.5M | 144.5M | 262.9M | 363.6M | 377.6M | 8.34M | 10.4M | 7.54M |
| Short-term investments | -1 | |||||||
| Receivables | 67.0M | 74.6M | 45.3M | 33.4M | 26.2M | 25.1M | 17.2M | 15.3M |
| Inventory | 37.0M | 30.2M | 20.6M | 10.3M | 6.95M | 5.45M | 3.87M | 4.13M |
| Current assets | 204.3M | 252.3M | 341.8M | 412.1M | 412.7M | 39.7M | 32.4M | 27.8M |
| Goodwill | 6.60M | 7.00M | 6.70M | 6.77M | 236.0K | 236.0K | ||
| Total assets | 469.7M | 473.8M | 510.1M | 500.6M | 456.9M | 74.4M | 73.7M | 48.2M |
| Accounts payable | 17.9M | 12.6M | 14.2M | 9.60M | 9.66M | 6.34M | 3.40M | 3.17M |
| Current liabilities | 70.9M | 72.6M | 62.9M | 51.2M | 29.4M | 28.0M | 15.9M | 9.75M |
| Long-term debt | 300.0K | 300.0K | 600.0K | 600.0K | 0 | 4.22M | ||
| Total debt | 51.9M | 59.1M | 74.8M | 21.2M | 13.0M | 21.5M | 23.9M | 9.72M |
| Total liabilities | 115.4M | 124.8M | 125.0M | 69.2M | 40.2M | 43.6M | 36.7M | 18.3M |
| Shareholders' equity | 354.3M | 349.1M | 385.1M | 431.4M | 416.7M | 30.8M | 37.0M | 30.0M |
| Shares outstanding | 16.6M | 16.4M | 16.2M | 15.9M | 11.2M | 2.90M | 3.03M | 3.00M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 8.20M | -46.8M | -69.7M | -40.5M | -16.5M | 627.0K | 14.6M | 6.02M |
| Capital spending | -1.50M | -76.9M | -32.0M | -25.8M | -8.80M | -3.41M | -9.31M | -5.06M |
| Free cash flow | 6.70M | -123.7M | -101.7M | -66.3M | -25.3M | -2.79M | 5.32M | 957.0K |
| Cash from investing | -70.7M | -76.9M | -32.0M | -23.9M | -10.3M | -4.71M | -9.96M | -5.06M |
| Cash from financing | -2.80M | 7.80M | -200.0K | 48.9M | 395.9M | 2.27M | -1.87M | -974.0K |
| Change in cash | -67.0M | -118.4M | -100.7M | -14.0M | 369.3M | -2.04M | 2.84M | -17.0K |
Cap table
Built by 6ix from Devyser Diagnostics AB’s releases
- Common shares
- 16,889,806
- Fully diluted
- 16,889,806
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 16,889,806 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 16,889,806 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Fredrik Dahl | Board member · Since at least Jul 22, 2025 |
| Jan Wahlström | CEO · Since at least Apr 27, 2026 |
| Mia Arnhult | Chairman · Since at least Jul 22, 2025 |
| Michael Uhlin | CSO · Since at least Apr 29, 2025 |
| Niklas Axelsson | CFO · Since at least Nov 4, 2026 |
| Olle Myrberg | VP Quality & Regulatory Affairs · Since at least Apr 29, 2025 |
| Olof Ericsson | Board member · Since at least Jul 22, 2025 |
| Pia Gideon | Board member · Since at least Jul 22, 2025 |
| Robin Sortebech | VP Supply Chain · Since at least Apr 29, 2025 |
| Sabina Berlin | VP IR & Corporate Affairs · Since at least Apr 27, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Thomas Eklund | Board member · Since at least Jul 22, 2025 |
Log in to ask 6ix AI your own questions about Devyser Diagnostics AB.